Published online before print May 31, 2007, doi: 10.1161/ATVBAHA.107.142570
© 2007 American Heart Association, Inc.
Brief Reviews |
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
From the TNO Quality of Life, Gaubius Laboratory, Department of Biosciences, Leiden, The Netherlands.
Correspondence to T. Kooistra, PhD, TNO Quality of Life, Gaubius Laboratory, Department of Biosciences, P.O. Box 2215, 2301 CE Leiden, The Netherlands. E-mail teake.kooistra{at}tno.nl
Atherosclerosis is a multifactorial highly-complex disease with numerous etiologies that work synergistically to promote lesion development. The ability to develop preventive and ameliorative treatments will depend on animal models that mimic the human subject metabolically and pathophysiologically and will develop lesions comparable to those in humans. The mouse is the most useful, economic, and valid model for studying atherosclerosis and exploring effective therapeutic approaches. Among the most widely used mouse models for atherosclerosis are apolipoprotein E–deficient (ApoE–/–) and LDL receptor–deficient (LDLr–/–) mice. An up-and-coming model is the ApoE*3Leiden (E3L) transgenic mouse. Here, we review studies that have explored how and to what extent these mice respond to compounds directed at treatment of the risk factors hypercholesterolemia, hypertriglyceridemia, hypertension, and inflammation. An important outcome of this survey is that the different models used may differ markedly from one another in their response to a specific experimental manipulation. The choice of a model is therefore of critical importance and should take into account the risk factor to be studied and the working spectrum of the compounds tested.
This review highlights some frequently used mouse models for atherosclerosis research and compares their responses to selective antiatherosclerotic manipulation.
Key Words: mouse models • atherosclerosis • pharmaceutical drugs • statins • ACE inhibitors • AT1 receptor antagonists • PPAR • LXR
This article has been cited by other articles:
 |
|
 |
|
  E. M. Quinet, M. D. Basso, A. R. Halpern, D. W. Yates, R. J. Steffan, V. Clerin, C. Resmini, J. C. Keith, T. J. Berrodin, I. Feingold, et al. LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse J. Lipid Res., December 1, 2009; 50(12): 2358 - 2370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Y. Foo, E. R. Heller, J. Wykrzykowska, C. J. Sullivan, J. J. Manning-Tobin, K. J. Moore, R. E. Gerszten, and A. Rosenzweig Vascular effects of a low-carbohydrate high-protein diet PNAS, September 8, 2009; 106(36): 15418 - 15423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Hartman, S. J. Gardell, C. J. Petucci, S. Wang, J. A. Krueger, and M. J. Evans Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice J. Lipid Res., June 1, 2009; 50(6): 1090 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. de Vries-van der Weij, W. de Haan, L. Hu, M. Kuif, H. L. D. W. Oei, J. W. A. van der Hoorn, L. M. Havekes, H. M. G. Princen, J. A. Romijn, J. W. A. Smit, et al. Bexarotene Induces Dyslipidemia by Increased Very Low-Density Lipoprotein Production and Cholesteryl Ester Transfer Protein-Mediated Reduction of High-Density Lipoprotein Endocrinology, May 1, 2009; 150(5): 2368 - 2375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Shaposhnik, X. Wang, J. Trias, H. Fraser, and A. J. Lusis The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002) J. Lipid Res., April 1, 2009; 50(4): 623 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Plump and P. Y. Lum Genomics and cardiovascular drug development. J. Am. Coll. Cardiol., March 31, 2009; 53(13): 1089 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Verschuren, J. de Vries-van der Weij, S. Zadelaar, R. Kleemann, and T. Kooistra LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms J. Lipid Res., February 1, 2009; 50(2): 301 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.F. Watts and D.C. Chan Of Mice and Men: Blowing Away the Cobwebs From the Mechanism of Action of Niacin on HDL Metabolism Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 1892 - 1895. [Full Text] [PDF]
|
|
|
|
|
|
J. W.A. van der Hoorn, W. de Haan, J. F.P. Berbee, L. M. Havekes, J. W. Jukema, P. C.N. Rensen, and H. M.G. Princen Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice Arterioscler Thromb Vasc Biol, November 1, 2008; 28(11): 2016 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gronros, J. Wikstrom, U. Brandt-Eliasson, G. B. Forsberg, M. Behrendt, G. I. Hansson, and L. M. Gan Effects of rosuvastatin on cardiovascular morphology and function in an ApoE-knockout mouse model of atherosclerosis Am J Physiol Heart Circ Physiol, November 1, 2008; 295(5): H2046 - H2053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Kleemann, S. Zadelaar, and T. Kooistra Cytokines and atherosclerosis: a comprehensive review of studies in mice Cardiovasc Res, August 1, 2008; 79(3): 360 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-S. Kuo, J. M. Kalbfleisch, P. Rutherford, D. Gifford-Moore, X.-d. Huang, R. Christie, K. Hui, K. Gould, and M. Rekhter Chemical analysis of atherosclerotic plaque cholesterol combined with histology of the same tissue J. Lipid Res., June 1, 2008; 49(6): 1353 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. de Haan, J. de Vries-van der Weij, J. W.A. van der Hoorn, T. Gautier, C. C. van der Hoogt, M. Westerterp, J. A. Romijn, J. W. Jukema, L. M. Havekes, H. M.G. Princen, et al. Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin Circulation, May 13, 2008; 117(19): 2515 - 2522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fukuda, M. Sata, N. Ishizaka, and R. Nagai Critical Role of Bone Marrow Angiotensin II Type 1 Receptor in the Pathogenesis of Atherosclerosis in Apolipoprotein E Deficient Mice Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 90 - 96. [Abstract] [Full Text] [PDF]
|
|